TY - JOUR
T1 - Recurrent IgA Nephropathy After Kidney Transplantation
AU - Nijim, S.
AU - Vujjini, V.
AU - Alasfar, S.
AU - Luo, X.
AU - Orandi, B.
AU - Delp, C.
AU - Desai, N. M.
AU - Montgomery, R. A.
AU - Lonze, Bonnie
AU - Alachkar, N.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background Immunoglobulin (Ig)A nephropathy is the most common primary glomerulonephritis worldwide, with a high recurrence rate after kidney transplantation. The aim of this study was to assess allograft survival, impact of recurrence on allograft function, and risk factors for post-transplant IgA recurrence. Methods We identified 104 patients with IgA nephropathy who underwent kidney transplantation at our center between 1993 and 2014. Fourteen patients underwent more than one allograft. Results IgA recurrence was documented in 23 (19%) allografts. Median time to recurrence was 6.75 years (interquartile range, 1.4–9.2 years). Twelve of the 23 recurrences were from living related donors (P =.07), and those with younger age at transplantation (37.7 ± 2.3 vs 44 ± 1.3, P =.05) were at higher risk of recurrence. Mean allograft survival was reduced in those with recurrence (6.5 ± 5.1 years) compared with those without recurrence (10.4 ± 7.5 years). At 6 years after transplant, allograft failure was documented in 52% of the recurrence group compared with 10% in the non-recurrence group (P = .002). Conclusions IgA recurrence after transplant is an important cause of allograft loss. Living related donors and younger age at transplantation are associated with high recurrence rate. Close monitoring and treatment of recurrence are crucial.
AB - Background Immunoglobulin (Ig)A nephropathy is the most common primary glomerulonephritis worldwide, with a high recurrence rate after kidney transplantation. The aim of this study was to assess allograft survival, impact of recurrence on allograft function, and risk factors for post-transplant IgA recurrence. Methods We identified 104 patients with IgA nephropathy who underwent kidney transplantation at our center between 1993 and 2014. Fourteen patients underwent more than one allograft. Results IgA recurrence was documented in 23 (19%) allografts. Median time to recurrence was 6.75 years (interquartile range, 1.4–9.2 years). Twelve of the 23 recurrences were from living related donors (P =.07), and those with younger age at transplantation (37.7 ± 2.3 vs 44 ± 1.3, P =.05) were at higher risk of recurrence. Mean allograft survival was reduced in those with recurrence (6.5 ± 5.1 years) compared with those without recurrence (10.4 ± 7.5 years). At 6 years after transplant, allograft failure was documented in 52% of the recurrence group compared with 10% in the non-recurrence group (P = .002). Conclusions IgA recurrence after transplant is an important cause of allograft loss. Living related donors and younger age at transplantation are associated with high recurrence rate. Close monitoring and treatment of recurrence are crucial.
UR - http://www.scopus.com/inward/record.url?scp=84994173002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994173002&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2016.08.011
DO - 10.1016/j.transproceed.2016.08.011
M3 - Article
C2 - 27788802
AN - SCOPUS:84994173002
VL - 48
SP - 2689
EP - 2694
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 8
ER -